long intergenic non-protein coding RNA 561Genealiases: []
Q-omics provides the consensus-scored LINC00561 profile across patient tissues and cancer cell-line models. LINC00561 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LINC00561 is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, LINC00561 RNA expression shows 8,524 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, BLCA, and TGCT as cancer lineages where LINC00561 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00561 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00561 survival associations across molecular data types. LINC00561 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00561 RNA expression–survival associations across cancer types. High LINC00561 expression shows unfavorable associations in CESC, KICH, LGG, BLCA and READ, but favorable associations in LUSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for LINC00561 RNA expression.
This table summarizes LINC00561 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00561. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00561 shows lower tumor expression in BLCA, HNSC, BRCA, STAD and READ. The BLCA box plot shows higher LINC00561 RNA expression in normal versus tumor tissue (log2 FC = −0.058, t-test p < 0.001).
This table shows molecular features associated with LINC00561 in patient tissues and cancer cell lines. In patient samples, LINC00561 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
